Cytokinetics, Incorporated (CYTK) Q4 FY25 Earnings Call

Commercial launch indicators are encouraging, but revenue visibility remains limited ahead of Acacia results and initial product sales.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-26
Length66 minutes
EPS$-1.50
EPS consensus$-1.48
Revenue$1.9M
Revenue consensus$8.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CYTK earnings ยท Back to CYTK overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.